Integrating pharmacovigilance to clinical pharmacy practice;Intégration de la pharmacovigilance à la pratique clinique

Journal de Pharmacie Clinique

Volumn 25, Issue 2, 2006, Pages 93-100

  Bussieres J F ^a   Blond, M ^a   Lebel, D ^a   Martin, B ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Adverse drug reaction; Pharmacovigilance; Underreporting

Indexed keywords

ARTICLE; CLINICAL PHARMACY; CLINICAL PRACTICE; COMPUTER SYSTEM; DRUG SURVEILLANCE PROGRAM; INTRANET; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; PUBLICATION; UNIVERSITY HOSPITAL;

EID: 33745683717     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Office québécois de la langue française - Grand Dictionnaire terminologique. http://www.granddictionnaire.com - site visité le 1-2-2006.
2. World Health Organisation (WHO). In: The importance of pharmacovigilance. Safety monitoring of medicinal product. Genève: WHO, 2002: 7.
3. Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988-1996. Med J Aust 1998; 168: 405-8.
4. Peyriere H, Cassan S, Floutard E, Riviere S, Blayac JP, Hillaire-Buys D, et al. Adverse drug events associated with hospital admission. Ann Pharmacotner 2003; 37: 5-11.
5. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Bégaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 55: 181-6.
6. Pouyanne P, Haramburu F, lmbs JL, Bégaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036.
7. van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 2006; 29: 161-8.
8. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
9. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8.
10. Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf 2000; 22: 161-8.
11. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200-5.
12. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. J Gen Intern Med 2005; 20: 317-23.
13. Gray SL, Mahoney JE, Blough DK. Adverse drug events in elderly patients receiving home nealth services following hospital discharge. Ann Pharmacother 1999; 33: 1147-53.
14. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29-34.
15. Darchy B, Le Miere E, Figueredo B, Bavoux E, Domart Y. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes and consequences. Arch Intern Med 1999; 159: 71-8.
16. Alvarez-Requejo A, Carvajal A, Bégaud B, Moride Y, Vega T, Martin Arias LH. Under-reporting of adverse drug reactions. Eur J Clin Pharmacol 1998; 54: 483-8.
17. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177-81.
18. Begaud B, Martin K, Haramburu F, Moore N. Rates of reporting of adverse drug reactions in France. JAMA 2002; 288: 1588.
19. Bäckström M, Mjörndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004; 13: 483-7.
20. Vallano A, Cereza G, Pedros C, Agusti A, Danés I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospitals. Br J Clin Pharmacol 2005; 60: 653-8.
21. Hasford J, Goettler M, Munter KH. Muller-Oerlinghausen. Physician's knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945-50.
22. Backstrom M, Mjorndal T, Dahlqvist R, Nordkvist-Olsson T. Attitudes to reporting adverse drug reactions in northen Sweden. Eur J Clin Pharmacol 2000; 56: 729-32.
23. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a northern Italian district. Pharmacol Res 1997; 35: 85-8.
24. Belton KJ, European Pharmacovigilance Research Group. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997; 52: 423-7.
25. Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol 2001; 56: 935-41.
26. Mckerrow R, Hall K, Bussières JF, Lefebvre P, McGregor P, Roberts N, et al. Rapport canadien sur la pharmacie hospitalière au Canada 2003-2004 - www.lillyhospitalsurvey.ca.
27. Centre hospitalier Sainte-Justine. Rapport annuel du département de pharmacie, 2004-2005.
28. Hughes ML, Whittlesea CMC, Luscombe KL. Review of national spontaneous reporting schemes. Adv Drug React Toxicol Rev 2002; 21: 231-41.
29. RRQ c. S-5, r.3.01 Règlement sur l'organisation et l'administration des établissements. Art. 105.
30. Carleton B, Poole R, Milton J, Travis J, Grinder D. The pediatric adverse drug reaction reporting system. J Ped Pharm Pract 1999; 4: 284-307.
31. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54: 665-70.
32. Sanz E, Boada J. Adverse drug reactions in paediatric outpatients. Int J Clin Pharmacol Res 1987; 7: 169-72.
33. Cirko-Begovic A, Vrhovac B, Bakran I. Intensive monitoring of adverse drug reactions in infants and preschool children. Eur J Clin Pharmacol 1989; 36: 63-5.
34. Trifiro G, Calogero G, Ippolito FM, Cosentino M, Giuliani R, Conforti A, et al. Adverse drug events in emergency department population: a prospective Italian study. Pharmacoepidemiol Drug Saf 2005; 14: 333-40.
35. Haffner S, Von Laue N, Wirth S, Thurmann PA. Detecting adverse drug reactions on paediatric wards. Drug Saf 2005; 28: 453-64.
36. Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ. A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 1999; 47: 681-8.
37. Neubert A, Dormann H, Weiss J, Egger T, Crieggee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 1059-67.
38. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paedatr 1999; 88: 965-8.
39. Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int J Clin Pharmacol Ther 1998; 36: 530-3.
40. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83.
41. van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004; 13: 457-64.
42. Backstrom M, Mjorndal T, Dahlqvist R. Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiol Drug Saf 2002; 11: 647-50.
43. Guzey C, Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions? Drug Saf 2002; 25: 553-60.
44. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pnarmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-9.
45. Kataoka S, Ohe K, Mochizuki M, Ueda S. Developing and integrating an adverse drug reaction reporting system with the hospital information system. Yakugaku Zasshi 2002; 122: 113-6.
46. Bates DW, Evans RS, Murff H, Stetson P, Pizziferri L, Hripcsak G. Detecting adverse events using information technology. JAMA 2003; 10: 115-28.
47. Classen DC, Pestotnik SL, Evans RS, Burke JP. Description of a computerized adverse drug event monitor using a hospital information system. Hosp Pharm 1992; 27: 774-83.
48. Lee SB, Schepers GP, Goldberg KL. Electronic adverse-drug-reaction- reporting program. Am J Health Syst Pharm 2004; 61: 1230-2.
49. Orsini MJ, Orsini PA, Thorn DB, Gallina JN. An ADR surveillance program: increasing quality, number of incidence reports. Formulary 1995; 30: 454-61.
50. Yee WP, Norton LL, Catania HF. Developing a comprehensive medication reaction reporting system. Hosp Pharm 1995; 30: 384-96.
51. Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health Syst Pharm 2002; 59: 1742-9.